Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) has launched the "Look at the Lids" education campaign aimed at raising awareness about Demodex blepharitis, a common eye condition affecting about 25 million U.S. patients. The campaign will be showcased at the upcoming American Academy of Ophthalmology and Optometry meetings and includes resources for eye care professionals to improve diagnosis rates. The initiative reflects Tarsus's commitment to advancing eyelid health and enhancing disease screening practices among eye care professionals.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced the upcoming presentation of positive data from the pivotal Phase 3 Saturn-2 trial of TP-03 at the World Cornea Congress VIII and AAO 2022. The company has submitted a New Drug Application (NDA) to the FDA, supported by favorable results from the Saturn-1 and Saturn-2 trials, which met primary and secondary endpoints. With no FDA-approved treatments for Demodex blepharitis currently available, TP-03 represents a significant advancement in addressing a condition affecting over 25 million patients in the U.S.

Tarsus Pharmaceuticals (NASDAQ: TARS) has submitted a New Drug Application (NDA) to the FDA for TP-03, an ophthalmic solution aimed at treating Demodex blepharitis. This condition, affecting approximately 25 million Americans, currently lacks FDA-approved treatments. The NDA is based on two pivotal trials involving over 800 patients, where TP-03 met all endpoints and was well-tolerated. If approved, TP-03 could revolutionize care for patients suffering from this common eyelid disease, which is caused by Demodex mite infestation.

Tarsus Pharmaceuticals (TARS) announced promising developments in its TP-03 drug for treating Demodex blepharitis, successfully meeting all endpoints in the Saturn-2 Phase 3 trial. The company expects to submit a New Drug Application (NDA) this year. Additionally, Tarsus has initiated a Phase 2a trial for TP-03 targeting Meibomian Gland Disease. Financially, Tarsus reported a net loss of $5.7 million for Q2 2022, a decrease from a net income of $6.3 million in Q2 2021, while cash reserves are projected to support operations through 2026.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has initiated a Phase 2a clinical trial to study TP-03 (lotilaner ophthalmic solution, 0.25%) for Meibomian Gland Disease (MGD) associated with Demodex mites. MGD affects approximately 22 million Americans and currently has no FDA-approved treatments. TP-03 showed significant efficacy in prior pivotal trials for Demodex blepharitis, enrolling over 800 patients. Tarsus plans to submit a New Drug Application for TP-03 for blepharitis later this year, signaling a strong commitment to expanding eye care therapeutics.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that its CEO, Bobak Azamian, will present a corporate update at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 8:30 AM PT. The presentation will focus on the company's mission to address unmet medical needs through innovative treatments, particularly in eye care. Tarsus is advancing two investigational medicines: TP-03 for Demodex blepharitis and TP-05 for Lyme disease prevention. A live webcast and further details are available on Tarsus's website.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced positive results from the Saturn-2 Phase 3 trial for TP-03, a treatment for Demodex blepharitis, achieving all primary and secondary endpoints. The company anticipates NDA submission in H2 2022 and expects a cash runway into at least 2026, supported by a recent $76 million public offering. Financial results for Q1 2022 showed a net loss of $20.2 million, down from a net income of $10.4 million in Q1 2021, with R&D expenses of $12.1 million. Cash, cash equivalents, and marketable securities totaled $175.3 million as of March 31, 2022.

Tarsus Pharmaceuticals has announced that Dr. Bobak Azamian, CEO, will present a corporate update at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 12:00pm PT / 3:00pm ET. The presentation will cover the company's focus on unmet needs in patient care, particularly in eye care. A live webcast of the event will be available on the company's website, with a replay accessible within 48 hours. Tarsus is advancing two investigational medicines, TP-03 and TP-05, targeting Demodex blepharitis and Lyme disease prevention respectively.

Tarsus Pharmaceuticals (NASDAQ: TARS) presented findings from the Atlas Continuation study, highlighting the burden of Demodex blepharitis on patients' lives at the ARVO 2022 Annual Meeting. The research showcases the need for effective treatments, as current options are inadequate. Furthermore, Tarsus plans to submit a New Drug Application for its lead treatment, TP-03, which showed positive results in pivotal trials involving 833 patients. This investigational therapy targets Demodex mites, offering hope for millions suffering from this condition.